Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis

BACKGROUND: The indication for treatment of type 1 diabetes(T1D) with the sodium–glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in Europe likely because of concern for diabetic ketoacidosis (DKA). We calculated the incidence of DKA in people with T1D treated with SGLT2i...

Descripción completa

Detalles Bibliográficos
Autores principales: Stougaard, Elisabeth B, Kristensen, Peter L, Kielgast, Urd, Andersen, Henrik U, Hamid, Yasmin, Gæde, Peter H, Søndergaard, Esben, Dørflinger, Gry H, Fjeldborg, Karen K, Hansen, Klavs W, Thomsen, Henrik H, Al-Imar, Thuraya M.J., Røder, Michael, Sridhar, Vikas S, Cherney, David, Rossing, Peter, Persson, Frederik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585567/
https://www.ncbi.nlm.nih.gov/pubmed/36262089
http://dx.doi.org/10.1177/14791641221130043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585567/
https://www.ncbi.nlm.nih.gov/pubmed/36262089
http://dx.doi.org/10.1177/14791641221130043

Ejemplares similares